[ + Watch Now + ]

Mobile Security Industry News

TMCNet:  Altravax, Inc. Awarded $3.45 Million in NIH Funds for Vaccines to HIV/AIDS

[December 03, 2012]

Altravax, Inc. Awarded $3.45 Million in NIH Funds for Vaccines to HIV/AIDS

FARGO, N.D. & SUNNYVALE, Calif. --(Business Wire)--

Altravax, Inc. announced today that it has been awarded two research grants worth a total of $3.45 million from the NIH's National Institute of Allergy and Infectious Diseases for research on antibody-inducing vaccines for HIV-1. UNAIDS, the Joint United Nations Programme on HIV/AIDS, reported that between 2.2 to 2.8 million people, including 330,000 children, were newly infected with HIV in 2011, bringing the total number of people living with AIDS to over 34 million. Altravax will use its proprietary MolecularBreeding™ directed evolution technology to create vaccines that provide broad protection against the various strains of HIV-1. The existence of a large number of virus strains and the continued changing nature of the virus is one of the major challenges facing the development of vaccines for HIV/AIDS.

Dr. Robert Whalen, the Chief Scientific Officer atAltravax, is a leader in the application of the MolecularBreeding™ technology platform to vaccine development. "We are pleased that the NIH has recognized the value of our technology in the search for an HIV vaccine. Our proposal to create vaccines that can more effectively stimulate the immune system represents a novel approach, and the recent award of these two grants will allow us to thoroughly explore this possibility. The current lack of viable vaccine candidates limits the ability of biotechnology companies to invest in HIV vaccine research with their own funds. We appreciate the federal government's willingness to support the goal of a preventative vaccine to combat the AIDS epidemic," said Dr. Whalen.


Altravax's latest research on vaccines for HIV/AIDS, performed by Dr. Kristin Narayan and colleagues from Altravax in collaboration with The Scripps Research Institute, will soon be published in the scientific journal PLoS ONE, an international, peer-reviewed, open-access, online publication.

In January 2010, Altravax acquired from Maxygen, Inc. (Nasdaq: MAXY) exclusive rights to the MolecularBreeding™ technology platform for the development of vaccines to infectious diseases. The Company has a focused product pipeline including vaccines to prevent or treat several infectious diseases.

About Altravax, Inc.

Altravax, Inc. is a privately held biopharmaceutical company with headquarters in Fargo, ND and research laboratories in Sunnyvale, CA (News - Alert). Altravax was founded based on the strength of a proven technology platform that can produce novel vaccine candidates with the potential to protect humans from infectious diseases and improve health globally.


[ Back To Mobile Security Homepage's Homepage ]

Follow Us

  • Mobile Security - LinkedIn
  • Mobile Security - Youtube
  • Mobile Security - Facebook
  • Mobile Security - Twitter
  • Mobile Security - RSS Feed

Request a Demo

Weekly Demonstration: SAP Mobile Secure
Solution including SAP Afaria Cloud

Free 30-day Trial

Best MDM in the cloud. Best MDM
Analytics. Best MDM price.

Featured Whitepapers

What Is Your Mobile Content Policy? A Checklist for Content Risk Mitigation
We are living in a world that only 20 years ago was the realm of science fiction. Devices once just barely imaginable have become common consumer items, carried casually in pockets and purses, with constantly growing capabilities.

SAP Enterprise Mobility: Bringing a Cohesive Approach to a Complex Market
Mobility and consumerization are creating complexity in the enterprise, but embracing the change can lead to more productive mobile workers as well as better communications with employees, partners, customers, and consumers. The trends in the enterprise mobility landscape drive a need for technology solutions to emerge.

Featured Datasheets

Securing Enterprise Mobility for Greater Competitive Advantage
We are living in a world that only 20 years ago was the realm of science fiction. Devices once just barely imaginable have become common consumer items, carried casually in pockets and purses, with constantly growing capabilities.

Secure Mobile Content Management for the Enterprise
Every day employees move business files onto their mobile devices so they can work at home, on the road, or at client sites. The mobile workforce is a reality, as 80% of employees say they need to access work documents from outside the office.1 Instead of insecure, consumer-based tools, enterprises need a safe, reliable platform for managing content on mobile devices.

Featured Webinar

Mobile Security - Mobile Drives Field Service Productivity at Satellites Unlimited

Mobile Drives Field Service Productivity at Satellites Unlimited
Field service has never been more competitive or faster changing than it is today. Going mobile is a must to stay ahead of the competition, provide improved services, and keep up with ever-increasing customer expectations.

Featured Webcast

Mobile Security - End to End Mobility Requirements: IDC and SAP explore the 3rd Platform

End to End Mobility Requirements: IDC and SAP explore the 3rd Platform
A new IDC study states that we're in the midst of a shift that takes place once every 20 - 25 years - introducing a new technology platform that will inspire growth and innovation for enterprises of all sizes. IDC calls it the 3rd Platform - built on mobile devices and apps, cloud services, mobile broadband networks, "Big Data", analytics, and social technologies.

Featured On-Demand Webinar

Mobile Security - Analyst Webcast: Secure Content Management in a Mobile Age

Analyst Webcast: Secure Content Management in a Mobile Age
Securing and managing content is taking on new importance as organizations try to cope with the explosion of business-oriented file sharing services while at the same time taking advantage of the proliferation of "smart" mobile devices.

Featured Infographics

Featured Press Releases